Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabies vaccine (animal) is a preclinical DNA/RNA-based vaccine candidate being developed by SET Technology for the prevention of rabies in animal populations. Utilizing SET Technology's proprietary nucleic acid delivery platform, the vaccine is designed to deliver genetic material encoding rabies virus antigens to elicit a protective immune response. The program is currently in the optimization or preclinical stage of development, representing a modern approach to veterinary immunization compared to traditional inactivated or live-attenuated vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine (animal).